Ocular Melanoma News and Research

RSS

MabCure featured in the August edition of Biotechnology Focus magazine

MabCure featured in the August edition of Biotechnology Focus magazine

MabCure, Inc. (“MabCure”), a biotechnology company using its proprietary technology to create highly specific monoclonal antibodies (MAbs) for the early detection of cancer, has been featured in the August edition of Biotechnology Focus, Canada's oldest and most successful magazine serving the Canadian life science industry.

31 Aug 2009

Delcath Systems enrolls 85 patients for its pivotal Phase III Metastatic Melanoma Trial

Delcath Systems enrolls 85 patients for its pivotal Phase III Metastatic Melanoma Trial

Delcath Systems, Inc., a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced today that it has exceeded 90% enrollment reaching 85 patients for its pivotal Phase III Metastatic Melanoma Trial.

25 Aug 2009

Sunbeds confirmed as cancer risk

Sunbeds confirmed as cancer risk

Sunbeds have been put in the highest cancer risk category by the international body charged with evaluating potential cancer hazards.

29 Jul 2009

Eye cancer patients want genetic testing to predict metastasis risk

Eye cancer patients want genetic testing to predict metastasis risk

If you had cancer and a genetic test could predict the risk of the tumor spreading aggressively, would you want to know - even if no treatments existed to help you?

1 Jun 2009

Delcath Systems enrols first fifty percent in trial treating metastatic cutaneous and ocular melanoma to the liver

Delcath Systems enrols first fifty percent in trial treating metastatic cutaneous and ocular melanoma to the liver

Delcath Systems, Inc. has announced that the first fifty percent (46 of 92) of patients have been enrolled in the Phase III clinical trial treating metastatic cutaneous and ocular melanoma to the liver.

12 Dec 2008

Medarex announces preliminary data for investigational anti-PD-1 antibody

Medarex announces preliminary data for investigational anti-PD-1 antibody

Medarex, Inc. has announced preliminary data from an ongoing Phase 1 study of MDX-1106 (ONO-4538: development code of Ono Pharmaceutical Co., Ltd.), a fully human anti-PD-1 antibody.

2 Jun 2008

Ocular melanoma - potential new treatment options

Ocular melanoma - potential new treatment options

Ocular melanoma is rarely detected before it has grown large enough to impair vision or to metastasize.

20 Feb 2008

Decitabine and interferon gamma show promise for ocular melanoma that has spread

Decitabine and interferon gamma show promise for ocular melanoma that has spread

A combination of two drugs shows promise in treating a rare and therapy-resistant type of melanoma that originates in the eye and spreads to other organs, according to a new study led by Duke University Comprehensive Cancer Center researchers.

5 Sep 2007

Treating malignant melanoma of the uvea with radiation therapy can spare patients from significant vision loss

Treating malignant melanoma of the uvea with radiation therapy can spare patients from significant vision loss

Treating a rare form of eye cancer with radiation therapy can spare patients from significant vision loss, according to new research at Wake Forest University Baptist Medical Center.

18 Oct 2005

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.